Therapeutic Consequences and Prognostic Impact of Multimorbidity in Heart Failure: Time to Act DOI Open Access
Fanni Bánfi‐Bacsárdi,

Ádám Kazay,

Tamás G. Gergely

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 139 - 139

Published: Dec. 29, 2024

Background/Objectives: In heart failure (HF) with reduced ejection fraction (HFrEF), the early diagnosis and proper treatment of comorbidities (CMs) are fundamental relevance. Our aim was to assess prevalence CMs among real-world patients requiring hospitalisation for HFrEF investigate effect on implementation guideline-directed medical therapy (GDMT) all-cause mortality (ACM). Methods: The data a consecutive patient cohort hospitalised HF between 2021 2024 were analysed retrospectively. Sixteen (6 CV 10 non-CV) considered. Patients divided into three categories: 0–3 vs. 4–6 ≥7 CMs. GDMT at discharge ACM compared CM categories. predictors 1-year also evaluated. Results: From 388 (male: 76%, age: 61 [50–70] years; NT-proBNP: 5286 [2570–9923] pg/mL; ≥2 cardiovascular–kidney–metabolic disease overlap: 46%), large proportion received (RASi: 91%; βB: 85%; MRA: 95%; SGLT2i: 59%; triple [TT: RASi+βB+MRA]: 82%; quadruple [QT: TT + SGLT2i]: 54%) discharge. Multimorbidity accompanied (p < 0.05) lower application ratio RASi (96% 92% CMs) βB (94% 85% 78%), while MRA (99% 94% 94%) SGTL2i use (61% 59% 57%) did not differ > 0.05). multimorbidity less likely be treated (93% 82% 73%, p = 0.001), no difference detected in QT (56% 54% 50%, 0.685). an increased burden higher (9% 13% 25%, 0.003). risk favourably affected by TT/QT severe left ventricular systolic dysfunction, having ≥5 had unfavourable impact prognosis. Conclusions: According our analysis, can expect favourable outcome. However, modern even applied this population, resulting significantly improved Thus, clinicians should insist early, conscious prognosis-modifying drug regime multimorbid as well.

Language: Английский

Therapeutic Consequences and Prognostic Impact of Multimorbidity in Heart Failure: Time to Act DOI Open Access
Fanni Bánfi‐Bacsárdi,

Ádám Kazay,

Tamás G. Gergely

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 139 - 139

Published: Dec. 29, 2024

Background/Objectives: In heart failure (HF) with reduced ejection fraction (HFrEF), the early diagnosis and proper treatment of comorbidities (CMs) are fundamental relevance. Our aim was to assess prevalence CMs among real-world patients requiring hospitalisation for HFrEF investigate effect on implementation guideline-directed medical therapy (GDMT) all-cause mortality (ACM). Methods: The data a consecutive patient cohort hospitalised HF between 2021 2024 were analysed retrospectively. Sixteen (6 CV 10 non-CV) considered. Patients divided into three categories: 0–3 vs. 4–6 ≥7 CMs. GDMT at discharge ACM compared CM categories. predictors 1-year also evaluated. Results: From 388 (male: 76%, age: 61 [50–70] years; NT-proBNP: 5286 [2570–9923] pg/mL; ≥2 cardiovascular–kidney–metabolic disease overlap: 46%), large proportion received (RASi: 91%; βB: 85%; MRA: 95%; SGLT2i: 59%; triple [TT: RASi+βB+MRA]: 82%; quadruple [QT: TT + SGLT2i]: 54%) discharge. Multimorbidity accompanied (p < 0.05) lower application ratio RASi (96% 92% CMs) βB (94% 85% 78%), while MRA (99% 94% 94%) SGTL2i use (61% 59% 57%) did not differ > 0.05). multimorbidity less likely be treated (93% 82% 73%, p = 0.001), no difference detected in QT (56% 54% 50%, 0.685). an increased burden higher (9% 13% 25%, 0.003). risk favourably affected by TT/QT severe left ventricular systolic dysfunction, having ≥5 had unfavourable impact prognosis. Conclusions: According our analysis, can expect favourable outcome. However, modern even applied this population, resulting significantly improved Thus, clinicians should insist early, conscious prognosis-modifying drug regime multimorbid as well.

Language: Английский

Citations

0